ACTOnco®+ Report

REPORT SUMMARY

REPORT DETAILS

APPENDIX

PATIENT AND SAMPLE INFORMATION

PATIENT	SPECIMEN	ORDERING PHYSICIAN
Name: 陳昭綺	Type: FFPE tissue	Name: 陳明晃醫師
Gender: Female	Date received: Oct 28, 2021	Facility: 臺北榮總
Date of Birth: May 03, 1965	Collection site: Colon	Tel: 886-228712121
Patient ID: 19749225	Specimen ID: S11030322	Address: 臺北市北投區石牌路二段 201 號
Diagnosis: Gastric adenocarcinoma	Lab ID: AA-21-04836	
	D/ID: NA	

VARIANT(S) WITH CLINICAL RELEVANCE

Only variant(s) with clinical significance are listed. See the "DETAILED TEST RESULTS" section for full details.

SINGLE NUCLEOTIDE AND SMALL INDEL VARIANTS

Not detected.

COPY NUMBER VARIANTS (CNVS)

Loss of heterozygosity (LOH) information was used to infer tumor cellularity. Copy number alteration in the tumor was determined based on **31%** tumor purity.

Amplification (Copy number ≥ 8)

Chr	Gene	Copy Number
ND	ND	ND

Homozygous deletion (Copy number=0)

Chr	Gene
ND	ND

Heterozygous deletion (Copy number=1)

Chr	Gene
chr5	*RAD50*
chr11	*ATM*
chr22	*CHEK2, NF2*

ND, Not Detected

TUMOR MUTATIONAL BURDEN (TMB)

1.9 muts/Mb

Muts/Mb, mutations per megabase

MICROSATELLITE INSTABILITY (MSI)

Microsatellite stable (MSS)

Note:
TMB was calculated by using the sequenced regions of ACTOnco®+ to estimate the number of somatic nonsynonymous mutations per megabase of all protein-coding genes (whole exome). The threshold for high mutation load is set at ≥ 7.5 mutations per megabase. TMB, microsatellite status and gene copy number deletion cannot be determined if calculated tumor purity is < 30%.

Variant Analysis:
醫檢師陳韻仔 博士
Yun-Yu Chen Ph.D.
檢字第 015647 號

Yun Yu Chen

Sign Off
醫檢師陳韻仔 博士
Yun-Yu Chen Ph.D.
檢字第 015647 號

Yun Yu Chen

陳昭綺
Project ID: C21-M001-01060
Report No.: AA-21-04836_ONC
Date Reported: Nov 10, 2021

THERAPEUTIC IMPLICATIONS

TARGETED THERAPIES

Genomic Alterations	Therapies	Effect
Level 3B		
ATM Heterozygous deletion	Niraparib, Olaparib, Rucaparib, Talazoparib	**sensitive**
CHEK2 Heterozygous deletion	Niraparib, Rucaparib	**sensitive**
Level 4		
CHEK2 Heterozygous deletion	Olaparib	**sensitive**
RAD50 Heterozygous deletion	Olaparib, Rucaparib	**sensitive**
NF2 Heterozygous deletion	Everolimus	**sensitive**

‡ Refer to "ONGOING CLINICAL TRIALS" section for detailed trial information.

Note: Therapies associated with benefit or lack of benefit are based on biomarkers detected in this tumor and published evidence.

Level		Description
1		FDA-recognized biomarker predictive of response to an FDA approved drug in this indication
2		Standard care biomarker (recommended as standard care by the NCCN or other expert panels) predictive of response to an FDA approved drug in this indication
3	A	Biomarkers that predict response or resistance to therapies approved by the FDA or professional societies for a different type of tumor
	B	Biomarkers that serve as inclusion criteria for clinical trials
4		Biomarkers that show plausible therapeutic significance based on small studies, few case reports or preclinical studies

IMMUNE CHECKPOINT INHIBITORS (ICI) THERAPIES

Genomic markers and alterations that are associated with response to ICI therapies

Positive Biomarker	Negative Biomarker
TMB-H: ND	EGFR aberration: ND
MSI-H: ND	MDM2/MDM4 amplification: ND
MMR biallelic inactivation: ND	STK11 biallelic inactivation: ND
PBRM1 biallelic inactivation: ND	PTEN biallelic inactivation: ND
SERPINB3/SERPINB4 mutation: ND	B2M biallelic inactivation: ND
	JAK1/2 biallelic inactivation: ND

MMR, mismatch repair; ND, not detected

Note: Tumor non-genomic factors, such as patient germline genetics, PDL1 expression, tumor microenvironment, epigenetic alterations or other factors not provided by this test may affect ICI response.

CHEMOTHERAPIES

No genomic alterations detected in this tumor predicted to confer sensitivity or lack of benefit to chemotherapies.

HORMONAL THERAPIES

No genomic alterations detected in this tumor predicted to confer sensitivity or lack of benefit to hormonal therapies.

OTHERS

No genomic alterations detected in this tumor predicted to confer sensitivity or lack of benefit to other therapies.

Note:
Therapeutic implications provided in the test are based solely on the panel of 440 genes sequenced. Therefore, alterations in genes not covered in this panel, epigenetic and post-transcriptional and post-translational factors may also determine a patient's response to therapies. In addition, several other patient-associated clinical factors, including but not limited to, prior lines of therapies received, dosage and combinations with other therapeutic agents, patient's cancer types, sub-types, and/or stages, may also determine the patient's clinical response to therapies.

VARIANT INTERPRETATION

ATM Heterozygous deletion

Biological Impact

The ataxia-telangiectasia mutated protein kinase (ATM) gene encodes a PI3K-related serine/threonine protein kinase involved in genomic integrity maintenance and plays central roles in DNA double-strand break (DSB) repair, which can be induced by ionizing radiation, chemotherapy drugs, or oxidative stress[1]. ATM is a well-characterized tumor suppressor gene, hereditary mutations and haploinsufficiency of ATM result in markedly increased susceptibility to a variety of cancer types[2][3][4][5][6]. Results from a case-cohort study of colorectal cancer and cancer-free control individuals suggested that germline pathogenic mutations in ATM and PALB2 should be added to established CRC risk genes as part of standard tumor genetic testing panels[7]. ATM is among the most commonly aberrant genes in sporadic cancers. Somatic ATM aberrations are frequently observed in hematologic malignancies[8][9][10][11]and a board range of tumors such as prostate cancer[12], head and neck squamous cell carcinoma (HNSCC)[13], pancreatic cancer[14], lung adenocarcinoma[15], breast cancer[16], and ovarian cancer[3].

Therapeutic and prognostic relevance

In May 2020, the U.S. FDA approved olaparib for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) who carry mutations in homologous recombination repair (HRR) genes, including BRCA1, BRCA2, ATM, BARD1, BRIP1, CDK12, CHEK1, CHEK2, FANCL, PALB2, RAD51B, RAD51C, RAD51D, RAD54L, and progressed following prior treatment with enzalutamide or abiraterone acetate[17].

In addition, ATM has been determined as an inclusion criterion for the trials evaluating rucaparib efficacy in ovarian cancer[18]or prostate cancer[19], niraparib efficacy in pancreatic cancer (NCT03553004), prostate cancer (NCT02854436), and any malignancy, except prostate (NCT03207347), and talazoparib efficacy in advanced or metastatic cancer (NCT02286687), HER2-negative breast cancer (NCT02401347), prostate cancer (NCT03148795), and lung cancer (NCT03377556), respectively.

Besides, another randomized, double-blind Phase II trial in patients with metastatic gastric cancer has shown that addition of olaparib to paclitaxel significantly increased the overall survival in both the overall population and patients with low or undetectable ATM protein expression[20]. Also, a prospective study in muscle-invasive bladder cancer patients suggested that genomic alternations in the DNA repair genes ATMs, RB1 and FANCC could be recognized as biomarkers predictive of response to cisplatin-based neoadjuvant chemotherapy[21]. However, loss-of-function of the ATM-CHEK2-TP53 cascade is associated with resistance to anthracycline/mitomycin-containing chemotherapy in patients with breast cancer[22].

A Retrospective study of the VICTOR clinical trial in patients with colorectal cancer showed that loss of expression of ATM is associated with worse prognosis[23].

CHEK2 Heterozygous deletion

Biological Impact

The checkpoint kinase 2 (CHEK2 or CHK2) gene encodes a serine/threonine protein kinase involved in transducing DNA damage signals that are required for both the intra-S phase and G2/M checkpoints[24]. CHEK2 heterozygosity has been shown to cause haploinsufficient phenotypes that can contribute to tumorigenesis through inappropriate S phase entry, accumulation of DNA damage during replication, and failure to restrain mitotic entry[25][26]. CHEK2 aberrations are associated with glioblastoma, breast, ovarian, prostate, colorectal, gastric, thyroid, and lung cancers[27][28][29][30][31].

Therapeutic and prognostic relevance

In May 2020, the U.S. FDA approved olaparib for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) who carry mutations in homologous recombination repair (HRR) genes, including BRCA1, BRCA2, ATM, BARD1, BRIP1, CDK12, CHEK1, CHEK2, FANCL, PALB2, RAD51B, RAD51C, RAD51D, RAD54L, and progressed following prior treatment with enzalutamide or abiraterone acetate[17].

In addition, CHEK2 has been determined as an inclusion criterion for the trials evaluating rucaparib efficacy in ovarian cancer[18]or prostate cancer[19](NCT03533946), niraparib efficacy in melanoma (NCT03925350), pancreatic cancer (NCT03553004), prostate cancer (NCT02854436), and any malignancy, except prostate (NCT03207347), and talazoparib efficacy in HER2-negative breast cancer (NCT02401347), prostate cancer (NCT03148795), and lung cancer (NCT03377556), respectively.

In a phase 2 trial, two prostate cancer patients harboring CHEK2 homozygous deletion was enrolled. One of the two patients had a response to olaparib[32].

NF2 Heterozygous deletion

Biological Impact

The neurofibromin (NF2) gene encodes the protein Merlin, a tumor suppressor that functions as a negative regulator of the PI3K/AKT/mTOR pathway[33][34][35]. NF2 is a haploinsufficient tumor suppressor gene with one copy loss may lead to weak protein expression and is insufficient to execute its original physiological functions[36]. Inactivation germline mutations in the NF2 are associated with the hereditary neurofibromatosis type 2, a disorder characterized by the growth of noncancerous tumors in the nervous system[33][37]. Somatic mutations or deletion of NF2 are frequently observed in human cancers, including 20-50% of pleural mesotheliomas[38], 6% papillary renal cell carcinoma, 5% pancreas cancer, and 4% melanoma (cbioPortal; June 2015), and less frequently in other cancers[39].

Therapeutic and prognostic relevance

Genomic alterations with activating effects on the mTOR signaling pathway have been identified to confer sensitivity to everolimus across multiple cancer types[40][41][42][43]. There are at least two case studies indicating the

clinical efficacy of everolimus in bladder cancer[44]and urothelial carcinoma[45], both harboring NF2 truncating mutations. Preclinical evidence has shown the efficacy of MEK1/2 inhibitor selumetinib in KRAS-mutant thyroid cancer model with NF2 loss[46].

Analysis of afatinib-plus-cetuximab-resistant biopsy specimens revealed a loss-of-function alteration in genes that modulate mTOR signaling pathway, including NF2 and TSC1[47].

***RAD50* Heterozygous deletion**

Biological Impact

The RAD50 gene encodes a highly-conserved DNA double-strand break (DSB) repair factor. It forms MRN complex with NBS1 and MRE11 protein and is involved in sensing and early processing of DSB, cell cycle checkpoints, DNA recombination and maintenance of telomeres[48][49]. Mutations in the components of the MRN complex could increase susceptibility to familial breast cancer[50][51], gastric cancer[52]colorectal cancer[53], and urothelial cancer[54]. RAD50 has been implicated as a haploinsufficient gene with one copy loss may lead to weak protein expression and is insufficient to execute its original physiological functions[55]. Besides, RAD50 deletion was also suggested as a marker of BRCAness, a phenotype shared between non-BRCA1/2-mutated ovarian cancers and BRCA1/2-mutated ovarian cancers[56].

Therapeutic and prognostic relevance

Preclinical data showed that knockdown of the RAD50 gene in ovarian cancer cell lines was significantly associated with better responses to two PARP inhibitors, olaparib and rucaparib[56].

陳昭綺
Project ID: C21-M001-01060
Report No.: AA-21-04836_ONC
Date Reported: Nov 10, 2021

US FDA-APPROVED DRUG(S)

Everolimus (AFINITOR)

Everolimus, a derivative of sirolimus, works as an inhibitor of mammalian target of rapamycin complex 1 (mTORC1) and blocks mTORC1-mediated downstream signals for cell growth, proliferation, and survival. Everolimus is developed and marketed by Novartis under the trade name AFINITOR.

FDA Approval Summary of Everolimus (AFINITOR)

RADIANT-4[57] NCT01524783	**Lung or gastrointestinal neuroendocrine tumor** (Approved on 2016/02/26)
	-
	Everolimus vs. Placebo [PFS(M): 11 vs. 3.9]
BOLERO-2[58] NCT00863655	**Breast cancer** (Approved on 2012/07/20)
	ER+/HER2-
	Everolimus + exemestane vs. Placebo + exemestane [PFS(M): 7.8 vs. 3.2]
RADIANT-3[59] NCT00510068	**Pancreatic neuroendocrine tumor** (Approved on 2011/05/05)
	-
	Everolimus vs. Placebo [PFS(M): 11 vs. 4.6]
EXIST-1[60] NCT00789828	**Subependymal giant cell astrocytoma** (Approved on 2010/10/29)
	-
	Everolimus vs. Placebo [ORR(%): 35.0]
RECORD-1[61] NCT00410124	**Renal cell carcinoma** (Approved on 2009/05/30)
	-
	Everolimus vs. Placebo [PFS(M): 4.9 vs. 1.9]

Niraparib (ZEJULA)

Niraparib is an oral, small molecule inhibitor of the DNA repair enzyme poly (ADP-ribose) polymerase-1 and -2 (PARP-1, -2). Niraparib is developed and marketed by Tesaro under the trade name ZEJULA.

FDA Approval Summary of Niraparib (ZEJULA)

QUADRA[62] NCT02354586	**Ovarian cancer** (Approved on 2019/10/23)
	HRD-positive (defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability)
	Niraparib [ORR(%): 24.0, DOR(M): 8.3]
NOVA[63] NCT01847274	**Ovarian cancer, Fallopian tube cancer, Peritoneal carcinoma** (Approved on 2017/03/27)
	gBRCA+ CR/PR to platinum-based chemotherapy
	Niraparib vs. Placebo [PFS(M): 21 vs. 5.5]
NOVA[63] NCT01847274	**Ovarian cancer, Fallopian tube cancer, Peritoneal carcinoma** (Approved on 2017/03/27)
	gBRCA- CR/PR to platinum-based chemotherapy
	Niraparib vs. Placebo [PFS(M): 9.3 vs. 3.9]

Olaparib (LYNPARZA)

Olaparib is an oral, small molecule inhibitor of poly (ADP-ribose) polymerase-1, -2, and -3 (PARP-1, -2, -3). Olaparib is developed by KuDOS Pharmaceuticals and marketed by AstraZeneca under the trade name LYNPARZA.

FDA Approval Summary of Olaparib (LYNPARZA)

PROfound[17] NCT02987543	**Prostate cancer** (Approved on 2020/05/19)
	ATMm, BRCA1m, BRCA2m, BARD1m, BRIP1m, CDK12m, CHEK1m, CHEK2m, FANCLm, PALB2m, RAD51Bm, RAD51Cm, RAD51Dm, RAD54Lm
	Olaparib vs. Enzalutamide or abiraterone acetate [PFS(M): 5.8 vs. 3.5]
PAOLA-1[64] NCT02477644	**Ovarian cancer** (Approved on 2020/05/08)
	HRD-positive (defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability)
	Olaparib + bevacizumab vs. Placebo + bevacizumab [PFS(M): 37.2 vs. 17.7]

POLO[65] NCT02184195	**Pancreatic adenocarcinoma** (Approved on 2019/12/27) **Germline BRCA mutation (deleterious/suspected deleterious)** Olaparib vs. Placebo [ORR(%): 23.0 vs. 12.0, PFS(M): 7.4 vs. 3.8]
SOLO-1[66] NCT01844986	**Ovarian cancer, Fallopian tube cancer, Peritoneal carcinoma** (Approved on 2018/12/19) **Germline or somatic BRCA-mutated (gBRCAm or sBRCAm)** Olaparib vs. Placebo [PFS(M): NR vs. 13.8]
OlympiAD[67] NCT02000622	**Breast cancer** (Approved on 2018/02/06) **Germline BRCA mutation (deleterious/suspected deleterious) HER2-negative** Olaparib vs. Chemotherapy [PFS(M): 7 vs. 4.2]
SOLO-2/ENGOT-Ov21[68] NCT01874353	**Ovarian cancer, Fallopian tube cancer, Peritoneal carcinoma** (Approved on 2017/08/17) **gBRCA+** Olaparib vs. Placebo [PFS(M): 19.1 vs. 5.5]
Study19[69] NCT00753545	**Ovarian cancer, Fallopian tube cancer, Peritoneal carcinoma** (Approved on 2017/08/17) - Olaparib vs. Placebo [PFS(M): 8.4 vs. 4.8]
Study 42[70] NCT01078662	**Ovarian cancer** (Approved on 2014/12/19) **Germline BRCA mutation (deleterious/suspected deleterious)** Olaparib [ORR(%): 34.0, DOR(M): 7.9]

Rucaparib (RUBRACA)

Rucaparib is an inhibitor of the DNA repair enzyme poly (ADP-ribose) polymerase-1, -2 and -3 (PARP-1, -2, -3). Rucaparib is developed and marketed by Clovis Oncology under the trade name RUBRACA.

FDA Approval Summary of Rucaparib (RUBRACA)

TRITON2 NCT02952534	**Prostate cancer** (Approved on 2020/05/15) **gBRCA+, sBRCA** Rucaparib [ORR(%): 44.0, DOR(M): NE]

ARIEL3[18] NCT01968213	**Ovarian cancer, Fallopian tube cancer, Peritoneal carcinoma** (Approved on 2018/04/06)
	All|HRD|tBRCA
	Rucaparib vs. Placebo [PFS (All)(M): 10.8 vs. 5.4, PFS (HRD)(M): 13.6 vs. 5.4, PFS (tBRCA)(M): 16.6 vs. 5.4]
ARIEL2[71] NCT01482715, NCT01891344	**Ovarian cancer** (Approved on 2016/12/19)
	Germline and/or somatic BRCA mutation
	Rucaparib [ORR(%): 54.0]

Talazoparib (TALZENNA)

Talazoparib is an inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, including PARP1 and PARP2. Talazoparib is developed and marketed by Pfizer under the trade name TALZENNA.

FDA Approval Summary of Talazoparib (TALZENNA)

EMBRACA[72] NCT01945775	**Breast cancer** (Approved on 2018/10/16)
	Germline BRCA mutation (deleterious/suspected deleterious) HER2-negative
	Talazoparib vs. Chemotherapy [PFS(M): 8.6 vs. 5.6]

d=day; w=week; m=month

陳昭綺
Project ID: C21-M001-01060
Report No.: AA-21-04836_ONC
Date Reported: Nov 10, 2021

ONGOING CLINICAL TRIALS

Clinical trials shown below were selected by applying filters: study status, patient's diagnosis, intervention, location and/or biomarker(s). Please visit https://clinicaltrials.gov to search and view for a complete list of open available and updated matched trials.

No trial has been found.

陳昭綺
Project ID: C21-M001-01060
Report No.: AA-21-04836_ONC
Date Reported: Nov 10, 2021

DETAILED TEST RESULTS

SINGLE NUCLEOTIDE AND SMALL INDEL VARIANTS

Gene	Chr	Exon	Accession Number	cDNA Change	Amino Acid Change	Coverage	Allele Frequency	COSMIC ID
ETV4	17	13	NM_001079675	c.1298C>T	P433L	488	51.8%	-
IL7R	5	8	NM_002185	c.1134C>G	D378E	870	47.6%	-
IL7R	5	3	NM_002185	c.314G>A	S105N	1225	47.3%	-
INSR	19	22	NM_000208	c.4115G>A	R1372Q	641	48.0%	-
KAT6A	8	-	NM_006766	c.600+5G>T	Splice region	814	54.8%	-
KDR	4	8	NM_002253	c.1055C>T	A352V	496	19.4%	-
LRP1B	2	53	NM_018557	c.8413T>C	C2805R	569	15.5%	COSM9312136
MUC16	19	3	NM_024690	c.10543C>T	H3515Y	539	48.8%	COSM371362
MUC16	19	19	NM_024690	c.37181T>A	F12394Y	1327	46.9%	-
NBN	8	5	NM_002485	c.505C>T	R169C	521	50.1%	-
PAX8	2	7	NM_003466	c.670C>T	R224C	618	49.2%	-
POLD1	19	16	NM_001256849	c.1932C>G	D644E	324	42.3%	-
PTEN	10	8	NM_000314	c.974_976dup	L325_D326insV	1079	18.7%	-
PTPRT	20	31	NM_007050	c.4289A>G	Y1430C	232	14.2%	-

Mutations with clinical relevance are highlighted in red.

陳昭綺

Project ID: C21-M001-01060
Report No.: AA-21-04836_ONC
Date Reported: Nov 10, 2021

COPY NUMBER VARIANTS (CNVS)

Observed copy number (CN) for each evaluated position is shown on the y-axis. Regions referred to as amplification or deletion are shown in color. Regions without significant changes are represented in gray.



陳昭綺
Project ID: C21-M001-01060
Report No.: AA-21-04836_ONC
Date Reported: Nov 10, 2021

HOTSPOT GENOTYPES

Listed variants are biomarkers or hotspots that are recommended as standard care by the NCCN or other expert panels and not necessarily FDA-recognized for a particular indication. The genotypes have been manually checked to ensure sufficient coverage for each hotspot of the target gene.

Gene	Variant	Genotype Detected
BRAF	V600X	Not detected
EGFR	A763_Y764insFQEA, E709K, E709_T710delinsD, Exon 19 deletion, Exon 19 insertion, Exon 20 insertion, G719A/C/D/S, L747P, L833V, L858R, L861Q/R, S768I, T790M	Not detected
IDH2	R140Q, R172G/K/M/S	Not detected
KIT	A502_Y503dup, D419del, D579del, D816F/V/Y, D820A/E/G/Y, E554_I571del, E554_K558del, E554_V559del, Exon 11 mutation, F522C, H697Y, I563_L576del, I653T, K550_W557del, K558N, K558_E562del, K558_V559del, K558delinsNP, K642E, M552_W557del, N505I, N564_Y578del, N822H/I/K/Y, P551_M552del, P573_D579del, P577_D579del, P577_W582delinsPYD, P838L, Q556_K558del, T417_D419delinsI, T417_D419delinsRG, T574_Q575insTQLPYD, V530I, V555_L576del, V555_V559del, V559A/C/D/G, V559_V560del, V559del, V560D/G, V560del, V569_L576del, V654A, W557G/R, W557_K558del, Y553N, Y553_K558del, Y570H, Y578C	Not detected
KRAS	A146T/V/P, G12X, G13X, Q61X	Not detected
MET	D1028H/N/Y	Not detected
NRAS	G12X, G13X, Q61X	Not detected
PDGFRA	A633T, C450_K451insMIEWMI, C456_N468del, C456_R481del, D568N, D842I/V, D842_H845del, D842_M844del, D846Y, E311_K312del, G853D, H650Q, H845Y, H845_N848delinsP, I843del, N659K/R/S, N848K, P577S, Q579R, R560_V561insER, R748G, R841K, S566_E571delinsR, S584L, V469A, V536E, V544_L545insAVLVLLVIVIISLI, V561A/D, V561_I562insER, V658A, W559_R560del, Y375_K455del, Y555C, Y849C/S	Not detected
PIK3CA	C420R, E542K/V, E545A/D/G/K, H1047X, Q546E/R	Not detected

V600X= any mutation in the valine (V) at amino acid 600 being replaced by a different amino acid.
G12X = any mutation in the glycine (G) at amino acid 12 being replaced by a different amino acid.
G13X= any mutation in the glycine (G) at amino acid 13 being replaced by a different amino acid.
Q61X = any mutation in the glutamine (Q) at amino acid 61 being replaced by a different amino acid.
H1047X = any mutation in the histidine (H) at amino acid 1047 being replaced by a different amino acid.

Gene	Copy Number Detected
CDK4	2
EGFR	3
ERBB2	2
MET	2

Copy number ≥ 8 is considered amplification

Other known alterations that are associated with sensitivity, resistance, and toxicity to therapies.

Gene	Variant	Genotype Detected
AKT1	E17K	Not detected
ALK	C1156Y, D1203N, G1202R, L1152R, S1206Y, T1151_L1152insT	Not detected
BRAF	K601E, L597V/Q/R/S	Not detected
DPYD	D949V, I560S, splice-site mutation	Not detected
EGFR	A750P, C797S/Y, S492R	Not detected
ERBB2	V659E	Not detected
ESR1	D538G, E380Q, L469V, L536H/P/Q/R, S432L, S463P, V422del, V534E, Y537C/N/S	Not detected
FGFR3	G370C, G380R, K650E/N/R/M/T/Q, R248C, S249C, S371C, Y373C	Not detected
IDH1	R132C/G/H/L/Q/S	Not detected
MAP2K1	D67N, E203K, F53L, K57E/N, P124S, Q56P, Q56_V60del, R47Q, R49L, S222D	Not detected
PTEN	R130*/fs/G/L/P/Q	Not detected
TPMT	A154T, Y240C	Not detected

Gene	Copy Number Detected
FGFR1	2
MDM2	2
MDM4	2

Copy number ≥ 8 is considered amplification

TEST DETAILS

ABOUT ACTOnco®+

The test is a next-generation sequencing (NGS)-based assay developed for efficient and comprehensive genomic profiling of cancers. This test interrogates coding regions of 440 genes associated with cancer treatment, prognosis and diagnosis. Genetic mutations detected by this test include small-scale mutations like single nucleotide variants (SNVs), small insertions and deletions (INDELs) (≤ 15 nucleotides) and large-scale genomic alterations like copy number variations (CNVs).

See ACTOnco®+ Gene List' Section for details of gene sequenced.

DATABASE USED

- Reference genome: human genome sequence hg19
- COSMIC v.92
- Genome Aggregation database r2.1.1
- ClinVar (version 20210208)
- ACT Genomics in-house database

NEXT-GENERATION SEQUENCING (NGS) METHODS

Extracted genomic DNA was amplified using four pools of primer pairs targeting coding exons of analyzed genes. Amplicons were ligated with barcoded adaptors. Quality and quantity of amplified library were determined using the fragment analyzer (AATI) and Qubit (Invitrogen). Barcoded libraries were subsequently conjugated with sequencing beads by emulsion PCR and enriched using Ion Chef system (Thermo Fisher Scientific) according to the Ion PI Hi-Q Chef Kit protocol (Thermo Fisher Scientific) or Ion 540 Kit-Chef protocol (Thermo Fisher Scientific). Sequencing was performed on the Ion Proton or Ion S5 sequencer (Thermo Fisher Scientific).

Raw reads generated by the sequencer were mapped to the hg19 reference genome using the Ion Torrent Suite (version 5.10). Coverage depth was calculated using Torrent Coverage Analysis plug-in. Single nucleotide variants (SNVs) and short insertions/deletions (INDELs) were identified using the Torrent Variant Caller plug-in (version 5.10). The coverage was down-sampled to 4000. VEP (Variant Effect Predictor) (version 100) was used to annotate every variant using databases from Clinvar (version 20210208), COSMIC v.92 and Genome Aggregation database r2.1.1. Variants with coverage ≥ 25, allele frequency ≥ 5% and actionable variants with allele frequency ≥ 2% were retained.

This test provides uniform coverage of the targeted regions, enabling target base coverage at 100x ≥ 85% with a mean coverage ≥ 500x.

Variants reported in Genome Aggregation database r2.1.1 with > 1% minor allele frequency (MAF) were

considered as polymorphisms. ACT Genomics in-house database was used to determine technical errors. Clinically actionable and biologically significant variants were determined based on the published medical literature.

The copy number variations (CNVs) were predicted as described below:
Amplicons with read counts in the lowest 5th percentile of all detectable amplicons and amplicons with a coefficient of variation ≥ 0.3 were removed. The remaining amplicons were normalized to correct the pool design bias. ONCOCNV (an established method for calculating copy number aberrations in amplicon sequencing data by Boeva et al., 2014) was applied for the normalization of total amplicon number, amplicon GC content, amplicon length, and technology-related biases, followed by segmenting the sample with a gene-aware model. The method was used as well for establishing the baseline of copy number variations from samples in ACT Genomics in-house database.

Tumor mutational burden (TMB) was calculated by using the sequenced regions of ACTOnco®+ to estimate the number of somatic nonsynonymous mutations per megabase of all protein-coding genes (whole exome). The TMB calculation predicted somatic variants and applied a machine learning model with a cancer hotspot correction. TMB may be reported as “TMB-High”, “TMB-Low” or “Cannot Be Determined”. TMB-High corresponds to ≥ 7.5 mutations per megabase (Muts/Mb); TMB-Low corresponds to < 7.5 Muts/Mb. TMB is reported as “Cannot Be Determined” if the tumor purity of the sample is < 30%.

Classification of microsatellite instability (MSI) status is determined by a machine learning prediction algorithm. The change of a number of repeats of different lengths from a pooled microsatellite stable (MSS) baseline in > 400 genomic loci are used as the features for the algorithm. The final output of the results is either microsatellite Stable (MSS) or microsatellite instability high (MSI-H).

STANDARD OPERATING PROCEDURES (SOPS)

Standard operating procedures (SOPs) are shown below:

- AG2-QP-15 Specimen Management Procedure
- AG3-QP16-03 SOP of Cancer Cell DNA and RNA Extraction
- AG3-QP16-07 SOP of Nucleic Acid Extraction with QIAsymphony SP
- AG3-QP16-08 SOP of FFPE Nucleic Acid Extraction
- AG3-QP16-10 SOP of HE Staining
- AG3-QP16-13 SOP of Library Construction and Preparation
- AG3-QP16-17 SOP of DNA Quantification with Qubit Fluorometer
- AG3-QP16-20 SOP of CE-Fragment Analysis
- AG3-QP16-22 SOP of Variant Calling
- AG3-QP16-24 SOP of Ion Torrent System Sequencing Reaction
- AG3-QP16-26 SOP of Ion Chef Preparation

- AG3-QP16-35 SOP of Variant Annotation
- AG3-QP16-96 SOP of Manual Inspection for SNVIndel Variant
- AG3-QP16-95 SOP of Manual Inspection for Copy Number Variant
- AG3-QP40-08 (02) Standard protocol for variant interpretation, curation and classification
- AG3-QP16-41 SOP of The user manual for clinical report system (CRS)

LIMITATIONS

This test does not provide information of variant causality and does not detect variants in non-coding regions that could affect gene expression. This report does not report polymorphisms and we do not classify whether a mutation is germline or somatic. Variants identified by this assay were not subject to validation by Sanger or other technologies.

NOTES

We do not exclude the possibility that pathogenic variants may not be reported by one or more of the tools and the parameters used.

PATHOLOGY EVALUATION

- H&E-stained section No.: S11030322
- Collection site: Colon
- Examined by: Dr. Yeh-Han Wang
- Estimated neoplastic nuclei (whole sample): The percentage of viable tumor cells in total cells in the whole slide (%): 20%
  The percentage of viable tumor cells in total cells in the encircled areas in the whole slide (%): 30%
  The percentage of necrotic cells (including necrotic tumor cells) in total cells in the whole slide (%): 0%
  The percentage of necrotic cells (including necrotic tumor cells) in total cells in the encircled areas in the whole slide (%): 0%
  Additional comment: NA
- Manual macrodissection: Performed on the highlighted region



The outline highlights the area of malignant neoplasm annotated by a pathologist.

SPECIMEN PHOTO(S)

- Collection date: Oct 2021
- Facility retrieved: 臺北榮總

RUN QC

- Panel: ACTOnco®+
- Mean Depth: 595x
- Target Base Coverage at 100x: 93%

陳昭綺

Project ID: C21-M001-01060
Report No.: AA-21-04836_ONC
Date Reported: Nov 10, 2021

ACTOnco®+ GENE LIST

ABCB1*	AURKB	CBL	CDKN2B	E2F3	FAT1	GRIN2A	JAK2	MED12	NOTCH4	PMS1	RAD51D	SLCO1B3*	TNFRSF14
ABCC2*	AXIN1	CCNA1	CDKN2C	EGFR	FBXW7	GSK3B	JAK3	MEF2B	NPM1	PMS2	RAD52	SMAD2	TNFSF11
ABCG2*	AXIN2	CCNA2	CEBPA*	EP300	FCGR2B	GSTP1*	JUN*	MEN1	NQO1*	POLB	RAD54L	SMAD3	TOP1
ABL1	AXL	CCNB1	CHEK1	EPCAM	FGF1*	GSTT1*	KAT6A	MET	NRAS	POLD1	RAF1	SMAD4	TP53
ABL2	B2M	CCNB2	CHEK2	EPHA2	FGF10	HGF	KDM5A	MITF	NSD1	POLE	RARA	SMARCA4	TPMT*
ADAMTS1	BAP1	CCNB3	CIC	EPHA3	FGF14	HIF1A	KDM5C	MLH1	NTRK1	PPARG	RB1	SMARCB1	TSC1
ADAMTS13	BARD1	CCND1	CREBBP	EPHA5	FGF19*	HIST1H1C*	KDM6A	MPL	NTRK2	PPP2R1A	RBM10	SMO	TSC2
ADAMTS15	BCL10	CCND2	CRKL	EPHA7	FGF23	HIST1H1E*	KDR	MRE11	NTRK3	PRDM1	RECQL4	SOCS1*	TSHR
ADAMTS16	BCL2*	CCND3	CRLF2	EPHB1	FGF3	HNF1A	KEAP1	MSH2	PAK3	PRKAR1A	REL	SOX2*	TYMS
ADAMTS18	BCL2L1	CCNE1	CSF1R	ERBB2	FGF4*	HR	KIT	MSH6	PALB2	PRKCA	RET	SOX9	U2AF1
ADAMTS6	BCL2L2*	CCNE2	CTCF	ERBB3	FGF6	HRAS*	KMT2A	MTHFR*	PARP1	PRKCB	RHOA	SPEN	UBE2A*
ADAMTS9	BCL6	CCNH	CTLA4	ERBB4	FGFR1	HSP90AA1	KMT2C	MTOR	PAX5	PRKCG	RICTOR	SPOP	UBE2K
ADAMTSL1	BCL9	CD19	CTNNA1	ERCC1	FGFR2	HSP90AB1	KMT2D	MUC16	PAX8	PRKCI	RNF43	SRC	UBR5
ADGRA2	BCOR	CD274	CTNNB1	ERCC2	FGFR3	HSPA4	KRAS	MUC4	PBRM1	PRKCQ	ROS1	STAG2	UGT1A1*
ADH1C*	BIRC2	CD58	CUL3	ERCC3	FGFR4	HSPA5	LCK	MUC6	PDCD1	PRKDC	RPPH1	STAT3	USH2A
AKT1	BIRC3	CD70*	CYLD	ERCC4	FH	IDH1	LIG1	MUTYH	PDCD1LG2	PRKN	RPTOR	STK11	VDR*
AKT2	BLM	CD79A	CYP1A1*	ERCC5	FLCN	IDH2	LIG3	MYC	PDGFRA	PSMB8	RUNX1	SUFU	VEGFA
AKT3	BMPR1A	CD79B	CYP2B6*	ERG	FLT1	IFNL3*	LMO1	MYCL	PDGFRB	PSMB9	RUNX1T1	SYK	VEGFB
ALDH1A1*	BRAF	CDC73	CYP2C19*	ESR1	FLT3	IGF1	LRP1B	MYCN	PDIA3	PSME1	RXRA	SYNE1	VHL
ALK	BRCA1	CDH1	CYP2C8*	ESR2	FLT4	IGF1R	LYN	MYD88	PGF	PSME2	SDHA	TAF1	WT1
AMER1	BRCA2	CDK1	CYP2D6	ETV1	FOXL2*	IGF2	MALT1	NAT2*	PHOX2B*	PSME3	SDHB	TAP1	XIAP
APC	BRD4	CDK12	CYP2E1*	ETV4	FOXP1	IKBKB	MAP2K1	NBN	PIK3C2B	PTCH1	SDHC	TAP2	XPO1
AR	BRIP1	CDK2	CYP3A4*	EZH2	FRG1	IKBKE	MAP2K2	NEFH	PIK3C2G	PTEN	SDHD	TAPBP	XRCC2
ARAF	BTG1*	CDK4	CYP3A5*	FAM46C	FUBP1	IKZF1	MAP2K4	NF1	PIK3C3	PTGS2	SERPINB3	TBX3	ZNF217
ARID1A	BTG2*	CDK5	DAXX	FANCA	GATA1	IL6	MAP3K1	NF2	PIK3CA	PTPN11	SERPINB4	TEK	
ARID1B	BTK	CDK6	DCUN1D1	FANCC	GATA2	IL7R	MAP3K7	NFE2L2	PIK3CB	PTPRD	SETD2	TERT	
ARID2	BUB1B	CDK7	DDR2	FANCD2	GATA3	INPP4B	MAPK1	NFKB1	PIK3CD	PTPRT	SF3B1	TET1	
ASXL1	CALR	CDK8	DICER1	FANCE	GNA11	INSR	MAPK3	NFKBIA	PIK3CG	RAC1	SGK1	TET2	
ATM	CANX	CDK9	DNMT3A	FANCF	GNA13	IRF4	MAX	NKX2-1*	PIK3R1	RAD50	SH2D1A*	TGFBR2	
ATR	CARD11	CDKN1A	DOT1L	FANCG	GNAQ	IRS1	MCL1	NOTCH1	PIK3R2	RAD51	SLC19A1*	TMSB4X*	
ATRX	CASP8	CDKN1B	DPYD	FANCL	GNAS	IRS2*	MDM2	NOTCH2	PIK3R3	RAD51B	SLC22A2*	TNF	
AURKA	CBFB	CDKN2A	DTX1	FAS	GREM1	JAK1	MDM4	NOTCH3	PIM1	RAD51C	SLCO1B1*	TNFAIP3	

*Analysis of copy number alteration not available.

DISCLAIMER

Legal Statement

This test was developed by ACT Genomics and its performing characteristics were determined by ACT Genomics. This test result is to be used for clinical consultative purposes only and is not intended as a substitute for a clinical guidance of your doctor or another qualified medical practitioner. It should not be regarded as investigational or used for research.

The detection of genomic alterations does not necessarily indicate pharmacologic effectiveness (or lack thereof) of any drug or treatment regimen; the detection of no genomic alteration does not necessarily indicate lack of pharmacologic effectiveness (or effectiveness) of any drug or treatment regimen.

Treatment Decisions are the Responsibility of the Physician

Decisions on clinical care and treatment should be based on the independent medical judgment of the treating physician, taking into consideration all applicable information concerning the patient's condition, including physical examinations, information from other diagnostics tests and patient preferences, in accordance with the standard of care in a given community. A treating physician's decisions should not be based on a single test, such as this test, or the information contained in this report.

In terms of consulting a different treating physician, the patient must file an application and fulfill the listed criteria for ACT Genomics to provide the patient's report to the assigned physician. The report may not be copied or reproduced except in its totality.

Genetic Alterations and Drugs Not Presented in Ranked Order

In this report, neither any biomarker alteration nor any drug associated with a potential clinical benefit (or potential lack of clinical benefit), are ranked in order of potential or predicted efficacy.

Level of Evidence Provided

Drugs with a potential clinical benefit (or potential lack of clinical benefit) are evaluated for level of published evidence with at least one clinical efficacy case report or preclinical study. We endeavor to keep the information in the report up to date. However, customers must be aware that scientific understanding and technologies change over time, and we make no warranty as to the accuracy, suitability or currency of information provided in this report at any time.

No Guarantee of Clinical Benefit

This report makes no promises or guarantees about the effectiveness of a particular drug or any treatment procedure in any disease or in any patient. This report also makes no promises or guarantees that a drug without an association of reportable genomic alteration will, in fact, provide no clinical benefit.

Liability

ACT Genomics is not affiliated with any medical facility or medical practitioner. We provide information for informational purposes only, therefore, ACT Genomics and their employees cannot be held responsible for any direct, indirect, special, incidental or consequential damages that may arise from the use of information provided in the report.

陳昭綺
Project ID: C21-M001-01060
Report No.: AA-21-04836_ONC
Date Reported: Nov 10, 2021

免責聲明

法律聲明

本檢驗報告僅提供專業醫療參考，結果需經專業醫師解釋及判讀。基因突變資訊非必具備藥物或治療有效性指標，反之亦然。本檢驗報告提供之用藥指引不聲明或保證其臨床有效性，反之亦然。本基因檢測方法係由本公司研究開發，已經過有效性測試。

本檢驗報告非經本公司許可，不得私自變造、塗改，或以任何方式作為廣告及其他宣傳之用途。
本公司於提供檢驗報告後，即已完成本次契約義務，後續之報告解釋、判讀及用藥、治療，應自行尋求相關專業醫師協助，若需將報告移件其他醫師，本人應取得該醫師同意並填寫移件申請書，主動告知行動基因，行動基因僅能配合該醫師意願與時間提供醫師解說。

醫療決策需由醫師決定

任何治療與用藥需經由醫師在考慮病患所有健康狀況相關資訊包含健檢、其他檢測報告和病患意願後，依照該地區醫療照護標準由醫師獨立判斷。醫師不應僅依據單一報告結果(例如本檢測或本報告書內容)做決策。

基因突變與用藥資訊並非依照有效性排序

本報告中列出之生物標記變異與藥物資訊並非依照潛在治療有效性排序。

證據等級

藥物潛在臨床效益(或缺乏潛在臨床效益)的實證證據是依據至少一篇臨床療效個案報告或臨床前試驗做為評估。本公司盡力提供適時及準確之資料，但由於醫學科技之發展日新月異，本公司不就本報告提供的資料是否為準確、適宜或最新作保證。

責任

本檢驗報告僅提供專業醫療參考，本公司及其員工不對任何由使用本報告之內容引起的直接、間接、特殊、連帶或衍生的損失或損害承擔責任。

陳昭綺
Project ID: C21-M001-01060
Report No.: AA-21-04836_ONC
Date Reported: Nov 10, 2021

SIGNALING PATHWAYS AND MOLECULAR-TARGETED AGENTS



1: Everolimus



1: Olaparib, Niraparib, Rucaparib, Talazoparib

REFERENCES

1. PMID: 22079189; 2012, Trends Biochem Sci;37(1):15-22
The ATM protein kinase and cellular redox signaling: beyond the DNA damage response.

2. PMID: 1548942; 1992, Leukemia;6 Suppl 1():8-13
Cancer susceptibility in ataxia-telangiectasia.

3. PMID: 12810666; 2003, Cancer Res;63(12):3325-33
Contributions of ATM mutations to familial breast and ovarian cancer.

4. PMID: 1961222; 1991, N Engl J Med;325(26):1831-6
Incidence of cancer in 161 families affected by ataxia-telangiectasia.

5. PMID: 28779002; 2017, J Med Genet;54(11):732-741
Rare, protein-truncating variants in ATM, CHEK2 and PALB2, but not XRCC2, are associated with increased breast cancer risks.

6. PMID: 16400190; 2006, Carcinogenesis;27(4):848-55
Atm-haploinsufficiency enhances susceptibility to carcinogen-induced mammary tumors.

7. PMID: 29478780; 2018, Am J Hum Genet;102(3):401-414
Inherited DNA-Repair Defects in Colorectal Cancer.

8. PMID: 9488043; 1998, Oncogene;16(6):789-96
ATM is usually rearranged in T-cell prolymphocytic leukaemia.

9. PMID: 11429421; 2001, J Clin Pathol;54(7):512-6
Ataxia telangiectasia gene mutations in leukaemia and lymphoma.

10. PMID: 11756177; 2002, Blood;99(1):238-44
ATM gene inactivation in mantle cell lymphoma mainly occurs by truncating mutations and missense mutations involving the phosphatidylinositol-3 kinase domain and is associated with increasing numbers of chromosomal imbalances.

11. PMID: 21993670; 2012, Haematologica;97(1):47-55
ATM gene alterations in chronic lymphocytic leukemia patients induce a distinct gene expression profile and predict disease progression.

12. PMID: 22981675; 2013, Eur Urol;63(5):920-6
Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity.

13. PMID: 22410096; 2012, Oral Oncol;48(8):698-702
Correlation of Ataxia-Telangiectasia-Mutated (ATM) gene loss with outcome in head and neck squamous cell carcinoma.

14. PMID: 23103869; 2012, Nature;491(7424):399-405
Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes.

15. PMID: 18948947; 2008, Nature;455(7216):1069-75
Somatic mutations affect key pathways in lung adenocarcinoma.

16. PMID: 30537493; 2019, Hum Pathol;86():85-92
Molecular characterization of metaplastic breast carcinoma via next-generation sequencing.

17. PMID: 32343890; 2020, N Engl J Med;382(22):2091-2102
Olaparib for Metastatic Castration-Resistant Prostate Cancer.

18. PMID: 28916367; 2017, Lancet;390(10106):1949-1961
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.

19. PMID: 32086346; 2020, Clin Cancer Res;26(11):2487-2496
Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study.

20. PMID: 26282658; 2015, J Clin Oncol;33(33):3858-65
Randomized, Double-Blind Phase II Trial With Prospective Classification by ATM Protein Level to Evaluate the Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer.

21. PMID: 26238431; 2015, Eur Urol;68(6):959-67
Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer.

22. PMID: 22420423; 2012, Breast Cancer Res;14(2):R47
Low expression levels of ATM may substitute for CHEK2 /TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer.

23. PMID: 23154512; 2012, Oncotarget;3(11):1348-55
Loss of expression of the double strand break repair protein ATM is associated with worse prognosis in colorectal cancer and loss of Ku70 expression is associated with CIN.

24. PMID: 21088254; 2011, Clin Cancer Res;17(3):401-5
Tumor suppressor CHK2: regulator of DNA damage response and mediator of chromosomal stability.

25. PMID: 15261141; 2004, Cancer Cell;6(1):45-59
Chk1 is haploinsufficient for multiple functions critical to tumor suppression.

26. PMID: 15539958; 2005, Cell Cycle;4(1):131-9
Chk1 is essential for tumor cell viability following activation of the replication checkpoint.

27. PMID: 23296741; 2013, Fam Cancer;12(3):473-8
The risk of gastric cancer in carriers of CHEK2 mutations.

28. PMID: 24713400; 2014, Hered Cancer Clin Pract;12(1):10
A risk of breast cancer in women - carriers of constitutional CHEK2 gene mutations, originating from the North - Central Poland.

29. PMID: 25583358; 2015, Int J Cancer;137(3):548-52
CHEK2 mutations and the risk of papillary thyroid cancer.

30. PMID: 12052256; 2002, Breast Cancer Res;4(3):R4
Mutation analysis of the CHK2 gene in breast carcinoma and other cancers.

31. PMID: 15125777; 2004, Mol Cancer;3():14
CHK2 kinase expression is down-regulated due to promoter methylation in non-small cell lung cancer.

32. PMID: 26510020; 2015, N Engl J Med;373(18):1697-708
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.

33. PMID: 25893302; 2016, Oncogene;35(5):537-48
Role of Merlin/NF2 inactivation in tumor biology.

34. PMID: 19451229; 2009, Mol Cell Biol;29(15):4235-49
Loss of the tumor suppressor gene NF2, encoding merlin, constitutively activates integrin-dependent mTORC1 signaling.

35. PMID: 19451225; 2009, Mol Cell Biol;29(15):4250-61
NF2/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth.

36. PMID: 17655741; 2007, Brain Pathol;17(4):371-6
Role of NF2 haploinsufficiency in NF2-associated polyneuropathy.

37. PMID: 19545378; 2009, Orphanet J Rare Dis;4():16
Neurofibromatosis type 2 (NF2): a clinical and molecular review.

38. PMID: 21642991; 2011, Nat Genet;43(7):668-72
The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma.

39. PMID: 24393766; 2014, Oncotarget;5(1):67-77
NF2/merlin in hereditary neurofibromatosis 2 versus cancer: biologic mechanisms and clinical associations.

40. PMID: 27091708; 2016, J Clin Oncol;34(18):2115-24
Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3.

41. PMID: 26503204; 2016, J Clin Oncol;34(5):419-26
Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From BOLERO-2.

42. PMID: 24833916; 2014, Breast Cancer (Dove Med Press);6():43-57
Use of mTOR inhibitors in the treatment of breast cancer: an evaluation of factors that influence patient outcomes.

43. PMID: 26859683; 2016, Oncotarget;7(9):10547-56
Next-generation sequencing reveals somatic mutations that confer exceptional response to everolimus.

44. PMID: 22923433; 2012, Science;338(6104):221
Genome sequencing identifies a basis for everolimus sensitivity.

45. PMID: 25630452; 2015, Eur Urol;67(6):1195-1196
Exceptional Response on Addition of Everolimus to Taxane in Urothelial Carcinoma Bearing an NF2 Mutation.

46. PMID: 26359368; 2015, Cancer Discov;5(11):1178-93
NF2 Loss Promotes Oncogenic RAS-Induced Thyroid Cancers via YAP-Dependent Transactivation of RAS Proteins and Sensitizes Them to MEK Inhibition.

47. PMID: 24813888; 2014, Cell Rep;7(4):999-1008
Acquired resistance of EGFR-mutant lung adenocarcinomas to afatinib plus cetuximab is associated with activation of mTORC1.

48. PMID: 9315668; 1997, Mol Cell Biol;17(10):6087-96
hMre11 and hRad50 nuclear foci are induced during the normal cellular response to DNA double-strand breaks.

49. PMID: 16467875; 2006, Cell Res;16(1):45-54
The role of NBS1 in DNA double strand break repair, telomere stability, and cell cycle checkpoint control.

50. PMID: 16385572; 2006, Int J Cancer;118(11):2911-6
Evaluation of RAD50 in familial breast cancer predisposition.

51. PMID: 24894818; 2014, Breast Cancer Res;16(3):R58
Rare key functional domain missense substitutions in MRE11A, RAD50, and NBN contribute to breast cancer susceptibility: results from a Breast Cancer Family Registry case-control mutation-screening study.

52. PMID: 18440592; 2008, Hum Pathol;39(6):925-32
Gastric cancer with high-level microsatellite instability: target gene mutations, clinicopathologic features, and long-term survival.

53. PMID: 11196187; 2001, Cancer Res;61(1):36-8
Frameshift mutations at coding mononucleotide repeats of the hRAD50 gene in gastrointestinal carcinomas with microsatellite instability.

54. PMID: 24934408; 2014, Cancer Discov;4(9):1014-21
Synthetic lethality in ATM-deficient RAD50-mutant tumors underlies outlier response to cancer therapy.

55. PMID: 16474176; 2006, Carcinogenesis;27(8):1593-9
RAD50 and NBS1 are breast cancer susceptibility genes associated with genomic instability.

56. PMID: 27016230; 2016, Gynecol Oncol;141(1):57-64
Copy number deletion of RAD50 as predictive marker of BRCAness and PARP inhibitor response in BRCA wild type ovarian cancer.

57. PMID: 26703889; 2016, Lancet;387(10022):968-977
Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study.

58. PMID: 22149876; 2012, N Engl J Med;366(6):520-9
Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.

59. PMID: 21306238; 2011, N Engl J Med;364(6):514-23
Everolimus for advanced pancreatic neuroendocrine tumors.

60. PMID: 23158522; 2013, Lancet;381(9861):125-32
Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial.

61. PMID: 18653228; 2008, Lancet;372(9637):449-56
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial.

62. PMID: 30948273; 2019, Lancet Oncol;20(5):636-648
Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial.

63. PMID: 27717299; 2016, N Engl J Med;375(22):2154-2164
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.

64. PMID: 31851799; 2019, N Engl J Med;381(25):2416-2428
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.

65. PMID: 31157963; 2019, N Engl J Med;381(4):317-327
Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer.

66. PMID: 30345884; 2018, N Engl J Med;379(26):2495-2505
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.

67. PMID: 28578601; 2017, N Engl J Med;377(6):523-533
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.

68. PMID: 28754483; 2017, Lancet Oncol;18(9):1274-1284
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.

69. PMID: 27617661; 2016, Lancet Oncol;17(11):1579-1589
Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.

70. PMID: 25366685; 2015, J Clin Oncol;33(3):244-50
Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.

71. PMID: 27908594; 2017, Lancet Oncol;18(1):75-87
Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.

72. PMID: 30110579; 2018, N Engl J Med;379(8):753-763
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation.

ACT GENOMICS®

CAP ACCREDITED COLLEGE of AMERICAN PATHOLOGISTS

ACTFusion™ Report

陳昭綺
Project ID: C21-M001-01060
Report No.: AA-21-04836_FUS
Date Reported: Nov 10, 2021

PATIENT	SPECIMEN	ORDERING PHYSICIAN
Name: 陳昭綺	Type: FFPE tissue	Name: 陳明晃醫師
Gender: Female	Date received: Oct 28, 2021	Facility: 臺北榮總
Date of Birth: May 03, 1965	Collection site: Colon	Tel: 886-228712121
Patient ID: 19749225	Specimen ID: S11030322	Address: 臺北市北投區石牌路二段 201 號
Diagnosis: Gastric adenocarcinoma	Lab ID: AA-21-04836	
	D/ID: NA	

ABOUT ACTFusion™

The test is a next-generation sequencing (NGS) based in vitro diagnostic assay to detect fusion transcripts of 13 genes, including *ALK, BRAF, EGFR, FGFR1, FGFR2, FGFR3, MET, NRG1, NTRK1, NTRK2, NTRK3, RET,* and *ROS1.*

VARIANT(S) WITH CLINICAL RELEVANCE

FUSION RESULTS

No fusion gene detected in this sample.

Variant Analysis:
醫檢師陳韻仔 博士
Yun-Yu Chen Ph.D.
檢字第 015647 號

Yun Yu Chen

Sign Off
醫檢師陳韻仔 博士
Yun-Yu Chen Ph.D.
檢字第 015647 號

Yun Yu Chen

陳昭綺
Project ID: C21-M001-01060
Report No.: AA-21-04836_FUS
Date Reported: Nov 10, 2021

THERAPEUTIC IMPLICATIONS

TARGETED THERAPIES

Not Applicable.

VARIANT INTERPRETATION

Not Applicable.

US FDA-APPROVED DRUG(S)

Not Applicable.

陳昭綺
Project ID: C21-M001-01060
Report No.: AA-21-04836_FUS
Date Reported: Nov 10, 2021

ONGOING CLINICAL TRIAL(S)

Clinical trials shown below were selected by applying filters: study status, patient's diagnosis, intervention, location and/or biomarker(s). Please visit https://clinicaltrials.gov to search and view for a complete list of open available and updated matched trials.

No trial has been found.

ACTFusion™ GENE LIST

ALK	*BRAF*	*EGFR*	*FGFR1*	*FGFR2*	*FGFR3*	*MET*	*NRG1*
NTRK1	*NTRK2*	*NTRK3*	*RET*	*ROS1*	-	-	-

TEST DETAILS

SPECIMEN RECEIVED



- H&E-stained section No.: S11030322
- Collection date: Oct 2021
- Collection site: Colon
- Facility retrieved: 臺北榮總
- Examined by: Dr. Yeh-Han Wang
- Estimated neoplastic nuclei (whole sample): The percentage of viable tumor cells in total cells in the whole slide (%): 20%
  The percentage of viable tumor cells in total cells in the encircled areas in the whole slide (%): 30%
  The percentage of necrotic cells (including necrotic tumor cells) in total cells in the whole slide (%): 0%
  The percentage of necrotic cells (including necrotic tumor cells) in total cells in the encircled areas in the whole slide (%): 0%
  Additional comment: NA
- Manual macrodissection: Performed on the highlighted region

The outline highlights the area of malignant neoplasm annotated by a pathologist.

陳昭綺
Project ID: C21-M001-01060
Report No.: AA-21-04836_FUS
Date Reported: Nov 10, 2021

NEXT-GENERATION SEQUENCING (NGS) METHODS

The extracted RNA was reverse-transcribed and subjected to library construction. The quality and quantity of the amplified library was determined using the fragment analyzer (AATI) and Qubit (Invitrogen). Sequencing was performed on the Ion 540™ Chip/ Ion 550™ Chip / Ion P1™ Chip and Ion GeneStudio™ S5 Prime System / Ion Proton™ System (Life Technologies). All assays were performed in accordance with ACT Genomics testing SOPs.

Data processing and statistical analysis for the identification of relevant fusions was performed using in-house fusion calling pipeline with default parameter setting. The four internal controls for the purpose of monitoring the overall sequencing quality of the sample were built into the assay, including CHMP2A, RABA7A, GPI, and VCP. Amplification of these genes using gene specific primers was performed, and the sequencing results were applied to the analysis pipeline to assess RNA quality. The inability of the software to detect these genes was considered a run failure. To ensure optimal sequencing quality for variant analysis, all samples had to meet the following sample quality control (QC) criteria: 1) Average unique RNA Start Sites (SS) per control Gene Specific Primer 2 (GSP 2) ≥ 10 (default), and 2) Total reads after sequencing ≥ 500,000 (recommended).

Samples passed the sample QC would be subjected to the fusion analysis pipeline for fusion transcript calling. Briefly, the analysis pipeline aligned sequenced reads to a reference genome, identified regions that map to noncontiguous regions of the genome, and applied filters to exclude probable false-positive events and annotate previously characterized fusion events. A minimum of 5 reads with 3 unique sequencing start sites that cross the breakpoints was set as the cutoff value to indicate strong evidence of fusions. RNA fusions would need to be in frame in order to generate productive transcripts. In addition, databases with details for documented fusions were used to authenticate the fusion sequence identified. Known fusions were queried using Quiver Gene Fusion Database, a curated database owned and maintained by ArcherDX. In summary, samples with detectable fusions had to meet the following criteria: 1) Number of unique start sites (SS) for the GSP2 ≥ 3. 2) Number of supporting reads spanning the fusion junction ≥ 5. 3) Percentage of supporting reads spanning the fusion junction ≥ 10%. 4) Fusions annotated in Quiver Gene Fusion Database.

DATABASE USED

Quiver Gene Fusion Database version 5.1.18

LIMITATIONS

This test has been designed to detect fusions in 13 genes sequenced. Therefore, fusion in genes not covered by this test would not be reported. For novel fusions detected in this test, Sanger sequencing confirmation is recommended if residue specimen is available.

STANDARD OPERATING PROCEDURES (SOPs)

Standard operating procedures (SOPs) are shown below:

- AG2-QP-15 Specimen Management Procedure
- AG3-QP16-08 SOP of FFPE Nucleic Acid Extraction
- AG3-QP16-10 SOP of HE Staining
- AG3-QP16-17 SOP of DNA Quantification with Qubit Fluorometer
- AG3-QP16-20 SOP of CE-Fragment Analysis
- AG3-QP16-24 SOP of Ion Torrent System Sequencing Reaction
- AG3-QP16-26 SOP of Ion Chef Preparation
- AG3-QP40-08 (02) Standard protocol for variant interpretation, curation and classification
- AG3-QP16-94 (01) SOP of ACTFusion v3 Library Construction and Preparation
- AG3-QP16-36(02) SOP of Fusion Gene Detection
- AG3-QP16-41 SOP of The user manual for clinical report system (CRS)

RUN QC

- Panel: ACTFusion™
- Total reads: 684374
- Average unique RNA Start Sites per control GSP2: 158

DISCLAIMER

Legal Statement

This test was developed by ACT Genomics and its performing characteristics were determined by ACT Genomics. This test result is to be used for clinical consultative purposes only and is not intended as a substitute for a clinical guidance of your doctor or another qualified medical practitioner. It should not be regarded as investigational or used for research.

The detection of genomic alterations does not necessarily indicate pharmacologic effectiveness (or lack thereof) of any drug or treatment regimen; the detection of no genomic alteration does not necessarily indicate lack of pharmacologic effectiveness (or effectiveness) of any drug or treatment regimen.

Treatment Decisions are the Responsibility of the Physician

Decisions on clinical care and treatment should be based on the independent medical judgment of the treating physician, taking into consideration all applicable information concerning the patient's condition, including physical examinations, information from other diagnostics tests and patient preferences, in accordance with the standard of care in a given community. A treating physician's decisions should not be based on a single test, such as this test, or the information contained in this report.

In terms of consulting a different treating physician, the patient must file an application and fulfill the listed criteria for ACT Genomics to provide the patient's report to the assigned physician. The report may not be copied or reproduced except in its totality.

Genetic Alterations and Drugs Not Presented in Ranked Order

In this report, neither any biomarker alteration nor any drug associated with a potential clinical benefit (or potential lack of clinical benefit), are ranked in order of potential or predicted efficacy.

Level of Evidence Provided

Drugs with a potential clinical benefit (or potential lack of clinical benefit) are evaluated for level of published evidence with at least one clinical efficacy case report or preclinical study. We endeavor to keep the information in the report up to date. However, customers must be aware that scientific understanding and technologies change over time, and we make no warranty as to the accuracy, suitability or currency of information provided in this report at any time.

No Guarantee of Clinical Benefit

This report makes no promises or guarantees about the effectiveness of a particular drug or any treatment procedure in any disease or in any patient. This report also makes no promises or guarantees that a drug without an association of reportable genomic alteration will, in fact, provide no clinical benefit.

Liability

ACT Genomics is not affiliated with any medical facility or medical practitioner. We provide information for informational purposes only, therefore, ACT Genomics and their employees cannot be held responsible for any direct, indirect, special, incidental or consequential damages that may arise from the use of information provided in the report.

陳昭綺
Project ID: C21-M001-01060
Report No.: AA-21-04836_FUS
Date Reported: Nov 10, 2021

免責聲明

法律聲明

本檢驗報告僅提供專業醫療參考，結果需經專業醫師解釋及判讀。基因突變資訊非必具備藥物或治療有效性指標，反之亦然。本檢驗報告提供之用藥指引不聲明或保證其臨床有效性，反之亦然。本基因檢測方法係由本公司研究開發，已經過有效性測試。

本檢驗報告非經本公司許可，不得私自變造、塗改，或以任何方式作為廣告及其他宣傳之用途。
本公司於提供檢驗報告後，即已完成本次契約義務，後續之報告解釋、判讀及用藥、治療，應自行尋求相關專業醫師協助，若需將報告移件其他醫師，本人應取得該醫師同意並填寫移件申請書，主動告知行動基因，行動基因僅能配合該醫師意願與時間提供醫師解說。

醫療決策需由醫師決定

任何治療與用藥需經由醫師在考慮病患所有健康狀況相關資訊包含健檢、其他檢測報告和病患意願後，依照該地區醫療照護標準由醫師獨立判斷。醫師不應僅依據單一報告結果(例如本檢測或本報告書內容)做決策。

基因突變與用藥資訊並非依照有效性排序

本報告中列出之生物標記變異與藥物資訊並非依照潛在治療有效性排序。

證據等級

藥物潛在臨床效益(或缺乏潛在臨床效益)的實證證據是依據至少一篇臨床療效個案報告或臨床前試驗做為評估。本公司盡力提供適時及準確之資料，但由於醫學科技之發展日新月異，本公司不就本報告提供的資料是否為準確、適宜或最新作保證。

責任

本檢驗報告僅提供專業醫療參考，本公司及其員工不對任何由使用本報告之內容引起的直接、間接、特殊、連帶或衍生的損失或損害承擔責任。

REFERENCES

Not Applicable.